|
1
|
Alphandéry E: Glioblastoma treatments: An
account of recent industrial developments. Front Pharmacol.
9:8792018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hanif F, Muzaffar K, Perveen K, Malhi SM
and Simjee SU: Glioblastoma multiforme: A review of its
epidemiology and pathogenesis through clinical presentation and
treatment. Asian Pacific J Cancer Prev. 18:3–9. 2017.PubMed/NCBI
|
|
3
|
Bai RY, Staedtke V and Riggins GJ:
Molecular targeting of glioblastoma: Drug discovery and therapies.
Trends Mol Med. 17:301–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kast RE, Ellingson BM, Marosi C and
Halatsch ME: Glioblastoma treatment using perphenazine to block the
subventricular zone's tumor trophic functions. J Neurooncol.
116:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wick W, Weller M, Weiler M, Batchelor T,
Yung AW and Platten M: Pathway inhibition: Emerging molecular
targets for treating glioblastoma. Neuro Oncol. 13:566–579. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masoumi KC, Huang X, Sime W, Mirkov A,
Munksgaard Thorén M, Massoumi R and Lundgren-Åkerlund E: Integrin
α10-antibodies reduce glioblastoma tumor growth and cell migration.
Cancers. 13:11842021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ellert-Miklaszewska A, Poleszak K,
Pasierbinska M and Kaminska B: Integrin signaling in glioma
pathogenesis: From biology to therapy. Int J Mol Sci. 21:8882020.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malric L, Monferran S, Gilhodes J, Boyrie
S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A,
Cohen-Jonathan Moyal E, et al: Interest of integrins targeting in
glioblastoma according to tumor heterogeneity and cancer stem cell
paradigm: An update. Oncotarget. 8:86947–86968. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee CC, Cheng YC, Chang CY, Lin CM and
Chang JY: Alpha-tubulin acetyltransferase/MEC-17 regulates cancer
cell migration and invasion through epithelial-mesenchymal
transition suppression and cell polarity disruption. Sci Rep.
8:174772018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Na TY, Schecterson L, Mendonsa AM and
Gumbiner BM: The functional activity of E-cadherin controls tumor
cell metastasis at multiple steps. Proc Natl Acad Sci USA.
117:5931–5937. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wick W, Osswald M, Wick A and Winkler F:
Treatment of glioblastoma in adults. Ther Adv Neurol Disord.
11:17562864187904522018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartek J and Hodny Z: Dopamine signaling:
Target in glioblastoma. Oncotarget. 5:1116–1117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Motohashi N, Kawase M, Satoh K and
Sakagami H: Cytotoxic potential of phenothiazines. Curr Drug
Targets. 7:1055–1066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sudeshna G and Parimal K: Multiple
non-psychiatric effects of phenothiazines: A review. Eur J
Pharmacol. 648:6–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Otręba M and Kośmider L: In vitro
anticancer activity of fluphenazine, perphenazine and
prochlorperazine. A review. J Appl Toxicol. 41:82–94. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Balça-Silva J, Matias D, Carmo AD,
Sarmento-Ribeiro AB, Lopes MC and Moura-Neto V: Cellular and
molecular mechanisms of glioblastoma malignancy: Implications in
resistance and therapeutic strategies. Semin Cancer Biol.
58:130–141. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Otręba M, Pajor M and Warncke JD:
Antimelanoma activity of perphenazine and prochlorperazine in human
COLO829 and C32 cell lines. Naunyn Schmiedebergs Arch Pharmacol.
392:1257–1264. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Atif F, Patel NR, Yousuf S and Stein DG:
The synergistic effect of combination progesterone and temozolomide
on human glioblastoma cells. PLoS One. 10:e01314412015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yelskaya Z, Carrillo V, Dubisz E, Gulzar
H, Morgan D and Mahajan SS: Synergistic inhibition of survival,
proliferation, and migration of U87 cells with a combination of
LY341495 and Iressa. PLoS One. 8:e645882013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Haque S, Norbert CC, Acharyya R, Mukherjee
S, Kathirvel M and Patra CR: Biosynthesized silver nanoparticles
for cancer therapy and in vivo bioimaging. Cancers. 13:61142021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sengul E and Elitas M: Single-cell
mechanophenotyping in microfluidics to evaluate behavior of U87
glioma cells. Micromachines (Basel). 11:8452020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kabała-Dzik A, Rzepecka-Stojko A, Kubina
R, Jastrzębska-Stojko Ż, Stojko R, Wojtyczka RD and Stojko J:
Migration rate inhibition of breast cancer cells treated by caffeic
acid and caffeic acid phenethyl ester: An in vitro comparison
study. Nutrients. 9:11442017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Grada A, Otero-Vinas M, Prieto-Castrillo
F, Obagi Z and Falanga V: Research techniques made simple: Analysis
of collective cell migration using the wound healing assay. J
Invest Dermatol. 137:e11–e16. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Devereaux J, Dargahi N, Fraser S, Nurgali
K, Kiatos D and Apostolopoulos V: Leucocyte-rich platelet-rich
plasma enhances fibroblast and extracellular matrix activity:
Implications in wound healing. Int J Mol Sci. 21:65192020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bernhart E, Damm S, Wintersperger A,
DeVaney T, Zimmer A, Raynham T, Ireson C and Sattler W: Protein
kinase D2 regulates migration and invasion of U87MG glioblastoma
cells in vitro. Exp Cell Res. 319:2037–2048. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Limame R, Wouters A, Pauwels B, Fransen E,
Peeters M, Lardon F, De Wever O and Pauwels P: Comparative analysis
of dynamic cell viability, migration and invasion assessments by
novel real-time technology and classic endpoint assays. PLoS One.
7:e465362012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li S, Li C, Ryu HH, Lim SH, Jang WY and
Jung S: Bacitracin inhibits the migration of U-87 MG glioma cells
via interferences of the integrin outside-in signaling pathway. J
Korean Neurosurg Soc. 59:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhao X, Sun Q, Dou C, Chen Q and Liu B:
BMP4 inhibits glioblastoma invasion by promoting E-cadherin and
claudin expression. Front Biosci (Landmark Ed). 24:1060–1070. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Otręba M and Buszman E: Perphenazine and
prochlorperazine induce concentration-dependent loss in human
glioblastoma cells viability. Die Pharmazie. 73:19–21.
2018.PubMed/NCBI
|
|
30
|
Muriithi W, Macharia LW, Heming CP,
Echevarria JL, Nyachieo A, Filho PN and Neto VM: ABC transporters
and the hallmarks of cancer: Roles in cancer aggressiveness beyond
multidrug resistance. Cancer Biol Med. 17:253–269. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Li Q, Zhou L, Xie N, Nice EC, Zhang
H, Huang C and Lei Y: Cancer drug resistance: Redox resetting
renders a way. Oncotarget. 7:42740–42761. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gupta SK, Singh P, Ali V and Verma M: Role
of membrane-embedded drug efflux ABC transporters in the cancer
chemotherapy. Oncol Rev. 14:4482020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin F, de Gooijer MC, Roig EM, Buil LC,
Christner SM, Beumer JH, Würdinger T, Beijnen JH and van Tellingen
O: ABCB1, ABCG2, and PTEN determine the response of glioblastoma to
temozolomide and ABT-888 therapy. Clin Cancer Res. 20:2703–2713.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wijaya J, Fukuda Y and Schuetz JD:
Obstacles to brain tumor therapy: Key ABC transporters. Int J Mol
Sci. 18:25442017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pan L, Lin H, Tian S, Bai D, Kong Y and Yu
L: The sensitivity of glioma cells to pyropheophorbide-αmethyl
ester-mediated photodynamic therapy is enhanced by inhibiting
ABCG2. Lasers Surg Med. 49:719–726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abdallah HM, Al-Abd AM, El-Dine RS and
El-Halawany AM: P-glycoprotein inhibitors of natural origin as
potential tumor chemo-sensitizers: A review. J Adv Res. 6:45–62.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang JS, Zhu HJ, Markowitz JS, Donovan JL,
Yuan HJ and Devane CL: Antipsychotic drugs inhibit the function of
breast cancer resistance protein. Basic Clin Pharmacol Toxicol.
103:336–341. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wesołowska O: Interaction of
phenothiazines, stilbenes and flavonoids with multidrug
resistance-associated transporters, P-glycoprotein and MRP1. Acta
Biochim Pol. 58:433–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Spengler G, Csonka Á, Molnár J and Amaral
L: The anticancer activity of the old neuroleptic
phenothiazine-type drug thioridazine. Anticancer Res. 36:5701–5706.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Abdallah IM, Al-Shami KM, Yang E and
Kaddoumi A: Blood-brain barrier disruption increases
amyloid-related pathology in TgSwDI mice. Int J Mol Sci.
22:12312021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Diop NK and Hrycyna CA: N-Linked
glycosylation of the human ABC transporter ABCG2 on asparagine 596
is not essential for expression, transport activity, or trafficking
to the plasma membrane. Biochemistry. 44:5420–5429. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sarafian V, Koev I and Staykov D:
Mechanisms of cell resistance in glioblastoma multiforme. J IMAB.
1:6–8. 2009.
|
|
43
|
Web page of International Union of Basic
and Clinical Pharmacology. https://www.guidetopharmacology.org/(access
08.02.2022).
|
|
44
|
Kast RE: Adding perphenazine to increase
effectiveness of standard glioblastoma chemoirradiation. J BUON.
25:1676–1686. 2020.PubMed/NCBI
|
|
45
|
Aaberg-Jessen C, Nørregaard A, Christensen
K, Pedersen CB, Andersen C and Kristensen BW: Invasion of primary
glioma- and cell line-derived spheroids implanted into
corticostriatal slice cultures. Int J Clin Exp Pathol. 6:546–560.
2013.PubMed/NCBI
|
|
46
|
Caragher SP, Shireman JM, Huang M, Miska
J, Atashi F, Baisiwala S, Hong Park C, Saathoff MR, Warnke L, Xiao
T, et al: Activation of dopamine receptor 2 prompts transcriptomic
and metabolic plasticity in glioblastoma. J Neurosci. 9:1982–1993.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Weissenrieder JS, Reed JL, Green MV,
Moldovan GL, Koubek EJ, Neighbors JD and Hohl RJ: The dopamine D2
receptor contributes to the spheroid formation behavior of U87
glioblastoma cells. Pharmacology. 105:19–27. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bhat K, Saki M, Vlashi E, Cheng F,
Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, et
al: The dopamine receptor antagonist trifluoperazine prevents
phenotype conversion and improves survival in mouse models of
glioblastoma. Proc Natl Acad Sci USA. 117:11085–11096. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Agrawal I, Sharma N, Saxena S, Arvind S,
Chakraborty D, Chakraborty DB, Jha D, Ghatak S, Epari S, Gupta T
and Jha S: Dopamine induces functional extracellular traps in
microglia. iScience. 24:1019682021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu Z, Jiang X, Gao L, Liu X, Li J, Huang
X and Zeng T: Synergistic suppression of glioblastoma cell growth
by combined application of temozolomide and dopamine D2 receptor
antagonists. World Neurosurg1. 28:e468–e477. 2019. View Article : Google Scholar
|
|
51
|
Arrillaga-Romany I, Odia Y, Prabhu VV,
Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M,
Batchelor TT and Wen PY: Biological activity of weekly ONC201 in
adult recurrent glioblastoma patients. Neuro Oncol. 22:94–102.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
He Y, Li J, Koga T, Ma J, Dhawan S, Suzuki
Y, Furnari F, Prabhu VV, Allen JE and Chen CC: Epidermal growth
factor receptor as a molecular determinant of glioblastoma response
to dopamine receptor D2 inhibitors. Neuro Oncol. 23:400–411. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Abbruzzese C, Matteoni S, Persico M,
Villani V and Paggi MG: Repurposing chlorpromazine in the treatment
of glioblastoma multiforme: Analysis of literature and forthcoming
steps. J Exp Clin Cancer Res. 39:262020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brasó-Maristany F, Filosto S, Catchpole S,
Marlow R, Quist J, Francesch-Domenech EA, Plumb D, Zakka L,
Gazinska P, Liccardi G, et al: PIM1 kinase regulates cell death,
tumor growth and chemotherapy response revealing a novel target in
triple-negative breast cancer. Nat Med. 22:1303–1313. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Herzog S, Fink MA, Weitmann K, Friedel C,
Hadlich S, Langner S, Kindermann K, Holm T, Böhm A, Eskilsson E, et
al: Pim1 kinase is upregulated in glioblastoma multiforme and
mediates tumor cell survival. Neuro Ooncol. 17:223–242. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Liang SC, Yang CY, Tseng JY, Wang HL, Tung
CY, Liu HW, Chen CY, Yeh YC, Chou TY, Yang MH, et al: ABCG2
localizes to the nucleus and modulates CDH1 expression in lung
cancer cells. Neoplasia. 17:265–278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bhatia P, Bernier M, Sanghvi M, Moaddel R,
Schwarting R, Ramamoorthy A and Wainer IW: Breast cancer resistance
protein (BCRP/ABCG2) localises to the nucleus in glioblastoma
multiforme cells. Xenobiotica. 42:748–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang S, Han L, Wei J, Shi Z, Pu P, Zhang
J, Yuan X and Kang C: Combination treatment with doxorubicin and
microRNA-21 inhibitor synergistically augments anticancer activity
through upregulation of tumor suppressing genes. Int J Oncol.
46:1589–1600. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Calinescu AA and Castro MG: Microtubule
targeting agents in glioma. Transl Cancer Res. 5 (Suppl 1):S54–S60.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Zhou Y, Wang Y, Wu S, Yan Y, Hu Y, Zheng
Z, Li J and Wu W: Sulforaphane-cysteine inhibited migration and
invasion via enhancing mitophagosome fusion to lysosome in human
glioblastoma cells. Cell Death Dis. 11:8192020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nakada M, Nambu E, Furuyama N, Yoshida Y,
Takino T, Hayashi Y, Sato H, Sai Y, Tsuji T, Miyamoto KI, et al:
Integrin α3 is overexpressed in glioma stem-like cells and promotes
invasion. Br J Cancer. 108:2516–2524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Hou J, Yan D, Liu Y, Huang P and Cui H:
The roles of integrin α5β1 in human cancer. Onco Targets Ther.
13:13329–13344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Mallawaaratchy DM, Buckland ME, McDonald
KL, Li CC, Ly L, Sykes EK, Christopherson RI and Kaufman KL:
Membrane proteome analysis of glioblastoma cell invasion. J
Neuropathol Exp Neurol. 74:425–441. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Renner G, Janouskova H, Noulet F, Koenig
V, Guerin E, Bär S, Nuesch J, Rechenmacher F, Neubauer S, Kessler
H, et al: Integrin α5β1 and p53 convergent pathways in the control
of anti-apoptotic proteins PEA-15 and survivin in high-grade
glioma. Cell Death Differ. 23:640–653. 2016. View Article : Google Scholar : PubMed/NCBI
|
